Innate immunity in HIV infection and implications for vaccine design: A summary of the workshop held at the National Institute of Allergy and Infectious Diseases, Bethesda on February 25-26, 2010

Vaccine

Volumn 28, Issue 52, 2010, Pages 8229-8235

  Bansal, Geetha P ^a   Leitner, Wolfgang W ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cross talk in innate adaptive immunity; Early acute HIV infection; HIV vaccines; Innate immunity

Indexed keywords

CYTOKINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; YELLOW FEVER VACCINE;

ADAPTIVE IMMUNITY; CONFERENCE PAPER; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE CONTROL; DRUG EFFICACY; DRUG RESEARCH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INFLUENZA; INNATE IMMUNITY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; VACCINATION; YELLOW FEVER;

AIDS VACCINES; HIV; HIV INFECTIONS; HUMANS; IMMUNITY, INNATE; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (U.S.); UNITED STATES;

EID: 78649747999     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.10.073     Document Type: Conference Paper

References (44)

1. Harris J.E. Why we don't have an HIV vaccine, and how we can develop one. Health Aff (Millwood) 2009, 28(6):1642-1654.
2. Bansal G.P., Malaspina A., Flores J. Future paths for HIV vaccine research: exploiting results from recent clinical trials and current scientific advances. Curr Opin Mol Ther 2010, 12(1):39-46.
3. Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H., Para M.F. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005, 191(5):654-665.
4. Pitisuttithum P., Gilbert P., Gurwith M., Heyward W., Martin M., van Griensven F., et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006, 194(12):1661-1671.
5. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., et al. HIV-1 vaccine-induced immunity in the test-of-concept step study: a case-cohort analysis. Lancet 2008, 372(9653):1894-1905.
6. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372(9653):1881-1893.
7. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361(23):2209-2220.
8. Haase A.T. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010, 464(7286):217-223.
9. Keele B.F., Giorgi E.E., Salazar-Gonzalez J.F., Decker J.M., Pham K.T., Salazar M.G., et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 2008, 105(21):7552-7557.
10. Levesque M.C., Moody M.A., Hwang K.K., Marshall D.J., Whitesides J.F., Amos J.D., et al. Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med 2009, 6(7):e1000107.
11. Walker L.M., Burton D.R. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol 2010, 22(3):358-366.
12. Pereira L.E., Ansari A.A. A case for innate immune effector mechanisms as contributors to disease resistance in SIV-infected sooty mangabeys. Curr HIV Res 2009, 7(1):12-22.
13. Pereira L.E., Onlamoon N., Wang X., Wang R., Li J., Reimann K.A., et al. Preliminary in vivo efficacy studies of a recombinant rhesus anti-alpha(4)beta(7) monoclonal antibody. Cell Immunol 2009, 259(2):165-176.
14. Favre D., Lederer S., Kanwar B., Ma Z.M., Proll S., Kasakow Z., et al. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog 2009, 5(2):e1000295.
15. Favre D., Mold J., Hunt P.W., Kanwar B., Loke P., Seu L., et al. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med 2010, 2(32):32ra6.
16. El Hed A., Khaitan A., Kozhaya L., Manel N., Daskalakis D., Borkowsky W., et al. Susceptibility of human Th17 cells to human immunodeficiency virus and their perturbation during infection. J Infect Dis 2010, 201(6):843-854.
17. + regulatory T cells. Proc Natl Acad Sci U S A 2009, 106(32):13439-13444.
18. Biron C.A. Activation and function of natural killer cell responses during viral infections. Curr Opin Immunol 1997, 9(1):24-34.
19. + NK cells during acute human immunodeficiency virus type 1 infection. J Virol 2009, 83(13):6798-6805.
20. Alter G., Martin M.P., Teigen N., Carr W.H., Suscovich T.J., Schneidewind A., et al. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med 2007, 204(12):3027-3036.
21. Pereira L.E., Johnson R.P., Ansari A.A. Sooty mangabeys and rhesus macaques exhibit significant divergent natural killer cell responses during both acute and chronic phases of SIV infection. Cell Immunol 2008, 254(1):10-19.
22. Webster R.L., Johnson R.P. Delineation of multiple subpopulations of natural killer cells in rhesus macaques. Immunology 2005, 115(2):206-214.
23. Cooper M.A., Colonna M., Yokoyama W.M. Hidden talents of natural killers: NK cells in innate and adaptive immunity. EMBO Rep 2009, 10(10):1103-1110.
24. Cella M., Fuchs A., Vermi W., Facchetti F., Otero K., Lennerz J.K., et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 2009, 457(7230):722-725.
25. O'Leary J.G., Goodarzi M., Drayton D.L., von Andrian U.H. T cell- and B cell-independent adaptive immunity mediated by natural killer cells. Nat Immunol 2006, 7(5):507-516.
26. Sun J.C., Beilke J.N., Lanier L.L. Immune memory redefined: characterizing the longevity of natural killer cells. Immunol Rev 2010, 236:83-94.
27. Ueno H., Schmitt N., Palucka A.K., Banchereau J. Dendritic cells and humoral immunity in humans. Immunol Cell Biol 2010, 88(4):376-380.
28. + regulatory T cells in human thymus. J Immunol 2010, 184(6):2999-3007.
29. + T cells. Proc Natl Acad Sci U S A 2009, 106(39):16776-16781.
30. Gasper-Smith N., Crossman D.M., Whitesides J.F., Mensali N., Ottinger J.S., Plonk S.G., et al. Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design. J Virol 2008, 82(15):7700-7710.
31. Frleta D., Yu C.I., Klechevsky E., Flamar A.L., Zurawski G., Banchereau J., et al. Influenza virus and poly(I:C) inhibit MHC class I-restricted presentation of cell-associated antigens derived from infected dead cells captured by human dendritic cells. J Immunol 2009, 182(5):2766-2776.
32. + Th1 immunity with poly IC as adjuvant. J Exp Med 2009, 206(7):1589-1602.
33. Gavin A.L., Hoebe K., Duong B., Ota T., Martin C., Beutler B., et al. Adjuvant-enhanced antibody responses in the absence of Toll-like receptor signaling. Science 2006, 314(5807):1936-1938.
34. Janssen E., Tabeta K., Barnes M.J., Rutschmann S., McBride S., Bahjat K.S., et al. Efficient T cell activation via a Toll-interleukin 1 receptor-independent pathway. Immunity 2006, 24(6):787-799.
35. Strutt T.M., McKinstry K.K., Dibble J.P., Winchell C., Kuang Y., Curtis J.D., et al. Memory CD4 T cells induce innate responses independent of pathogen. Nat Med 2010, 16(5):558-564.
36. Li Q., Estes J.D., Schlievert P.M., Duan L., Brosnahan A.J., Southern P.J., et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature 2009, 458(7241):1034-1038.
37. Stacey A.R., Norris P.J., Qin L., Haygreen E.A., Taylor E., Heitman J., et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 2009, 83(8):3719-3733.
38. + T cell responses. J Immunol 2008, 180(1):350-360.
39. Ansari A.A., Mayne A.E., Sundstrom J.B., Bostik P., Grimm B., Altman J.D., et al. Administration of recombinant rhesus interleukin-12 during acute simian immunodeficiency virus (SIV) infection leads to decreased viral loads associated with prolonged survival in SIVmac251-infected rhesus macaques. J Virol 2002, 76(4):1731-1743.
40. Querec T.D., Akondy R.S., Lee E.K., Cao W., Nakaya H.I., Teuwen D., et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009, 10(1):116-125.
41. Bosinger S.E., Li Q., Gordon S.N., Klatt N.R., Duan L., Xu L., et al. Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J Clin Invest 2009, 119(12):3556-3572.
42. Pascual V., Chaussabel D., Banchereau J. A genomic approach to human autoimmune diseases. Annu Rev Immunol 2010, 28:535-571.
43. Beutler B., Jiang Z., Georgel P., Crozat K., Croker B., Rutschmann S., et al. Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large. Annu Rev Immunol 2006, 24:353-389.
44. Paust S, Gill HS, Wang BZ, Flynn MP, Moseman EA, Senman B, et al. Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. Nat Immunol 2010 Oct 24 [Epub ahead of print].